Head-To-Head Comparison: Oric Pharmaceuticals (NASDAQ:ORIC) and Scholar Rock (NASDAQ:SRRK)

Oric Pharmaceuticals (NASDAQ:ORIC) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Insider and Institutional Ownership

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oric Pharmaceuticals and Scholar Rock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Scholar Rock	N/A	-163.52%	-96.67%

Risk & Volatility

Oric Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Oric Pharmaceuticals and Scholar Rock, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1	2	14	0	2.76
Scholar Rock	1	0	12	4	3.12

Oric Pharmaceuticals presently has a consensus price target of $18.92, suggesting a potential upside of 98.50%. Scholar Rock has a consensus price target of $56.00, suggesting a potential upside of 2.26%. Given Oric Pharmaceuticals’ higher possible upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than Scholar Rock.

Valuation and Earnings

This table compares Oric Pharmaceuticals and Scholar Rock”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47 million	($1.44)	-6.62
Scholar Rock	N/A	N/A	-$377.94 million	($3.59)	-15.25

Scholar Rock is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Oric Pharmaceuticals beats Scholar Rock on 9 of the 12 factors compared between the two stocks.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.